Adverum Biotechnologies, Inc. - Common Stock (ADVM)

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.

In today's session, these stocks are experiencing unusual volume.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the second quarter of 2024.

Adverum Biotechnologies presented 26-week interim data from the LUNA Phase 2 trial for Ixo-vec in wet AMD. The analysis showed significant reductions in anti-VEGF injections and positive visual outcomes.

ADVM stock results show that Adverum Biotechnologies missed analyst estimates for earnings per share the first quarter of 2024.

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.

ADVM stock results show that Adverum Biotechnologies beat analyst estimates for earnings per share the fourth quarter of 2023.

There are plenty of penny stocks ready to pop but we have to remember that penny stocks are extremely risky, too.

Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments

Our economy is doing well, and these top penny stocks are in position to benefit from this. Invest now and see strong returns.

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.